Table 1.
Anti-MAYV mAbs
AntibodyIsotypeKD, equilibriumCHBeH407FSB0311IQU2950OBS2209UrumaBeH343155BeH506151TRVL15537BeH473130BeH428890
MAY-115 IgG2a n.b. 2 (1–4) 2 (1–3) 5 (3–9) 7 (4–14) 9 (5–17) 1 (1–3) 166 (93–102) 33 (14–67) 32 (17–61) 64 (36–115) 92 (54–146) 
MAY-116 IgG1 20 ± 2 11 (9–16) 37 (19–76) 54 (23–105) 11 (5–15) 3 (1–5) 11 (11–15) 15 (8–32) 65 (32–135) 10 (6–20) 23 (11–49) 19 (4–96) 
MAY-117 IgG1 11 ± 3 5 (3–9) 4 (2–9) 5 (3–11) 28 (16–51) 3 (2–6) 57 (26–113) 8 (3–18) 18 (10–33) 60 (27–120) 9 (6–17) 39 (18–85) 
MAY-118 IgG1 13 ± 4 2 (1–3) 6 (2–13) 3 (2–5) 24 (13–45) 33 (16–71) 48 (29–95) 16 (7–34) 8 (4–15) 12 (10–33) 36 (17–69) 11 (7–18) 
MAY-119 IgG1 14 ± 4 2 (1–4) 16 (9–31) 1 (1–3) 25 (14–55) 2 (1–4) 19 (10–36) 8 (5–17) 20 (13–39) 50 (28–102) 23 (10–46) 25 (13–47) 
MAY-120 IgG1 18 ± 1 3 (1–6) 10 (5–20) 6 (3–11) 5 (2–10) 1 (1–2) 41 (25–72) 3 (1–7) 68 (32–140) 26 (12–55) 13 (5–28) 22 (14–36) 
MAY-121 IgG1 47 ± 13 4 (2–6) 20 (11–36) 7 (4–11) 33 (23–49) 3 (2–8) 5 (4–7) 280 (175–450) 34 (23–49) 34 (15–83) 28 (19–50) 45 (22–92) 
MAY-122 IgG2a 4 ± 1 2 (1–6) 3 (2–6) 6 (3–10) 11 (4–32) 6 (3–13) 5 (4–8) 10 (6–16) 7 (6–8) 7 (3–13) 5 (3–11) 6 (4–10) 
MAY-125 IgG2a 58 ± 19 5 (3–10) 22 (14–42) 5 (2–12) 10 (6–19) 10 (5–21) 61 (28–122) 30 (21–43) 9 (3–17) 103 (52–213) 25 (17–58) 35 (24–53) 
MAY-130 IgG1 3 ± 1 1 (1–2) 5 (3–10) 1 (1–2) 4 (110) 3 (1–10) 2 (1–4) 2 (1–3) 25 (14–41) 41 (27–62) 5 (2–13) 3 (2–4) 
MAY-131 IgG2a n.b. 7 (312) 8 (2–14) 3 (1–5) 14 (11–17) 12 (4–29) 22 (15–30) 64 (22–104) 42 (36–47) 22 (13–32) 61 (45–78) 43 (32–55) 
MAY-133 IgG2a 243 ± 64 38 (14–106) 25 (14–44) 34 (25–32) 50 (28–91) 3 (2–5) >10,000 31 (22–46) 42 (30–57) 1,911 (940–4,429) 30 (18–51) 39 (21–75) 
MAY-134 IgG2a 152 ± 69 4 (2–7) 9 (4–13) 27 (19–39) 50 (37–90) 3 (2–4) 17 (12–23) 33 (21–53) 34 (27–44) 26 (18–38) 41 (27–62) 44 (22–90) 
MAY-139 IgG2a 22 ± 11 36 (17–77) 246 (133–342) 22 (8–65) 38 (15–103) 3 (1–15) 62 (38–105) 27 (17–42) 26 (16–42) 33 (8–159) 27 (15–29) 39 (21–75) 
MAY-140 IgG2a 170 ± 29 1,315 (408–6,040) 18 (11–30) >10,000 4 (2–8) >10,000 69 (19–345) 5 (2–6) 3,788 (732–6,403) 3 (1–15) >10,000 2 (1–3) 
MAY-146 IgG1 18 ± 5 30 (26–34) 63 (55–72) 42 (37–47) 22 (14–30) 47 (22–89) 33 (19–345) 74 (65–83) 29 (24–36) 57 (30–84) 85 (64–106) 73 (65–82) 
MAY-147 IgG1 38 ± 8 23 (15–30) 16 (11–22) 98 (58–169) 233 (96–630) 11 (4–27) 18 (9–25) 88 (37–229) 108 (28–151) 105 (43–269) 41 (22–77) 112 (71–178) 
MAY-151 IgG1 29 ± 7 66 (48–55) 52 (47–57) 6 (2–18) 59 (29–87) 52 (42–83) 27 (20–35) 7 (2–13) 78 (66–91) 21 (17–26) 8 (4–14) 5 (1–11) 
AntibodyIsotypeKD, equilibriumCHBeH407FSB0311IQU2950OBS2209UrumaBeH343155BeH506151TRVL15537BeH473130BeH428890
MAY-115 IgG2a n.b. 2 (1–4) 2 (1–3) 5 (3–9) 7 (4–14) 9 (5–17) 1 (1–3) 166 (93–102) 33 (14–67) 32 (17–61) 64 (36–115) 92 (54–146) 
MAY-116 IgG1 20 ± 2 11 (9–16) 37 (19–76) 54 (23–105) 11 (5–15) 3 (1–5) 11 (11–15) 15 (8–32) 65 (32–135) 10 (6–20) 23 (11–49) 19 (4–96) 
MAY-117 IgG1 11 ± 3 5 (3–9) 4 (2–9) 5 (3–11) 28 (16–51) 3 (2–6) 57 (26–113) 8 (3–18) 18 (10–33) 60 (27–120) 9 (6–17) 39 (18–85) 
MAY-118 IgG1 13 ± 4 2 (1–3) 6 (2–13) 3 (2–5) 24 (13–45) 33 (16–71) 48 (29–95) 16 (7–34) 8 (4–15) 12 (10–33) 36 (17–69) 11 (7–18) 
MAY-119 IgG1 14 ± 4 2 (1–4) 16 (9–31) 1 (1–3) 25 (14–55) 2 (1–4) 19 (10–36) 8 (5–17) 20 (13–39) 50 (28–102) 23 (10–46) 25 (13–47) 
MAY-120 IgG1 18 ± 1 3 (1–6) 10 (5–20) 6 (3–11) 5 (2–10) 1 (1–2) 41 (25–72) 3 (1–7) 68 (32–140) 26 (12–55) 13 (5–28) 22 (14–36) 
MAY-121 IgG1 47 ± 13 4 (2–6) 20 (11–36) 7 (4–11) 33 (23–49) 3 (2–8) 5 (4–7) 280 (175–450) 34 (23–49) 34 (15–83) 28 (19–50) 45 (22–92) 
MAY-122 IgG2a 4 ± 1 2 (1–6) 3 (2–6) 6 (3–10) 11 (4–32) 6 (3–13) 5 (4–8) 10 (6–16) 7 (6–8) 7 (3–13) 5 (3–11) 6 (4–10) 
MAY-125 IgG2a 58 ± 19 5 (3–10) 22 (14–42) 5 (2–12) 10 (6–19) 10 (5–21) 61 (28–122) 30 (21–43) 9 (3–17) 103 (52–213) 25 (17–58) 35 (24–53) 
MAY-130 IgG1 3 ± 1 1 (1–2) 5 (3–10) 1 (1–2) 4 (110) 3 (1–10) 2 (1–4) 2 (1–3) 25 (14–41) 41 (27–62) 5 (2–13) 3 (2–4) 
MAY-131 IgG2a n.b. 7 (312) 8 (2–14) 3 (1–5) 14 (11–17) 12 (4–29) 22 (15–30) 64 (22–104) 42 (36–47) 22 (13–32) 61 (45–78) 43 (32–55) 
MAY-133 IgG2a 243 ± 64 38 (14–106) 25 (14–44) 34 (25–32) 50 (28–91) 3 (2–5) >10,000 31 (22–46) 42 (30–57) 1,911 (940–4,429) 30 (18–51) 39 (21–75) 
MAY-134 IgG2a 152 ± 69 4 (2–7) 9 (4–13) 27 (19–39) 50 (37–90) 3 (2–4) 17 (12–23) 33 (21–53) 34 (27–44) 26 (18–38) 41 (27–62) 44 (22–90) 
MAY-139 IgG2a 22 ± 11 36 (17–77) 246 (133–342) 22 (8–65) 38 (15–103) 3 (1–15) 62 (38–105) 27 (17–42) 26 (16–42) 33 (8–159) 27 (15–29) 39 (21–75) 
MAY-140 IgG2a 170 ± 29 1,315 (408–6,040) 18 (11–30) >10,000 4 (2–8) >10,000 69 (19–345) 5 (2–6) 3,788 (732–6,403) 3 (1–15) >10,000 2 (1–3) 
MAY-146 IgG1 18 ± 5 30 (26–34) 63 (55–72) 42 (37–47) 22 (14–30) 47 (22–89) 33 (19–345) 74 (65–83) 29 (24–36) 57 (30–84) 85 (64–106) 73 (65–82) 
MAY-147 IgG1 38 ± 8 23 (15–30) 16 (11–22) 98 (58–169) 233 (96–630) 11 (4–27) 18 (9–25) 88 (37–229) 108 (28–151) 105 (43–269) 41 (22–77) 112 (71–178) 
MAY-151 IgG1 29 ± 7 66 (48–55) 52 (47–57) 6 (2–18) 59 (29–87) 52 (42–83) 27 (20–35) 7 (2–13) 78 (66–91) 21 (17–26) 8 (4–14) 5 (1–11) 

IgG subclasses, KD, equilibrium values, and neutralization values of the 18 inhibitory anti-MAYV mAbs. IgG subclasses were determined by ELISA. KD, equilibrium values (nanomoles) were measured by BLI using recombinant MAYV E2 protein. EC50 values (ng/ml) along with 95% confidence intervals (in parentheses) were calculated from FRNT. Data are the mean and 95% confidence of two experiments performed in triplicate. Bold font indicates antibodies with elite neutralizing activity (<10 ng/ml) against the indicated MAYV strain. n.b., nonbinding.

or Create an Account

Close Modal
Close Modal